18.47BMarket Cap-11.11P/E (TTM)
16.220High14.670Low17.93MVolume14.690Open14.670Pre Close283.29MTurnover1.57%Turnover RatioLossP/E (Static)1.15BShares22.80052wk High3.44P/B18.38BFloat Cap12.51052wk Low--Dividend TTM1.14BShs Float68.007Historical High--Div YieldTTM10.57%Amplitude3.107Historical Low15.801Avg Price1Lot Size
Teva Pharmaceutical Industries Stock Forum
Can Teva's Injectable UZEDY Revolutionize Bipolar I Disorder Treatment? FDA Now Reviewing
$Greenwave Technology Solutions (GWAV.US)$
$Professional Diversity Network (IPDN.US)$
$Nuburu (BURU.US)$
$NewGenIvf (NIVF.US)$
$Pony AI (PONY.US)$
$Huize (HUIZ.US)$
$Teva Pharmaceutical Industries (TEVA.US)$
$Alvotech (ALVO.US)$
$NaaS Technology (NAAS.US)$
Can This New IBD Drug Outperform Current Treatments? Phase 2b Data Shows Remarkable 48% Remission Rate
FDA-Approved SELARSDI Launches: What Makes This Stelara® Alternative Different?
Major Eye Treatment Breakthrough: FDA Reviews New Affordable Eylea Alternative
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals (CPRX) and its licensor SERB S.A. have reached a settlement agreement with Teva Pharmaceuticals regarding patent litigation over FIRDAPSE® (amifampridine). The litigation was initiated after Teva filed an Abbreviated New Drug Application seeking to market a generic version o...
No comment yet